Robert D. McQuade, PhD

Efficacy and Safety of Adjunctive Brexpiprazole in MDD

May 22, 2018

Finding effective treatment for depressed patients who do not adequately respond to antidepressant medications is a frequent challenge for clinicians. Read this article to learn about the efficacy, safety,...

Mary Hobart, Aleksandar Skuban, Peter Zhang, et al

Original Research

Aripiprazole to Treat Bipolar Disorder

March 29, 2017

Read a randomized control trial evaluating the efficacy and safety of once-monthly long-acting injectable antipsychotic aripiprazole.

Joseph R. Calabrese, Raymond Sanchez, Na Jin, et al

Original Research

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

September 23, 2015

Michael E. Thase, James M. Youakim, Aleksandar Skuban, et al

Original Research

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

September 23, 2015

Michael E. Thase, James M. Youakim, Aleksandar Skuban, et al

Original Research

Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia: Findings From a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

August 19, 2014

John M. Kane, Timothy Peters-Strickland, Ross A. Baker, et al

Original Research

A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder

January 15, 2014

Robert L. Findling, Raymond Mankoski, Karen Timko, et al

Original Research

Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

May 15, 2012

John M. Kane, Raymond Sanchez, Pamela P. Perry, et al

Article

Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study

July 26, 2011

Ronald N. Marcus, Randall Owen, George Manos, et al

Article

Acute Treatment of Pediatric Bipolar I Disorder, Manic or Mixed Episode, With Aripiprazole: A Randomized, Double-Blind, Placebo-Controlled Study

October 15, 2009

Robert L. Findling, Margaretta Nyilas, Robert A. Forbes, et al

Original Research

The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia: A Pooled Post Hoc Analysis From 5 Short-Term Studies

December 2, 2008

Philip G. Janicak, Ira D. Glick, Stephen R. Marder, et al

Original Research

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

July 31, 2008

John W. Newcomer, Joao Alberto Campos, Ronald N. Marcus, et al

Original Research

Predicted Risk of Diabetes and Coronary Heart Disease in Patients With Schizophrenia: Aripiprazole Versus Standard of Care

May 11, 2008

Lawrence Blonde, Hong J. Kan, Elane M. Gutterman, et al

Efficacy and Safety of Adjunctive Brexpiprazole in MDD

Aripiprazole to Treat Bipolar Disorder

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia: Findings From a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder

Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study

Acute Treatment of Pediatric Bipolar I Disorder, Manic or Mixed Episode, With Aripiprazole: A Randomized, Double-Blind, Placebo-Controlled Study

The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia: A Pooled Post Hoc Analysis From 5 Short-Term Studies

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

Predicted Risk of Diabetes and Coronary Heart Disease in Patients With Schizophrenia: Aripiprazole Versus Standard of Care

ELSEWHERE:

FOLLOW US:

Robert D. McQuade, PhD

Efficacy and Safety of Adjunctive Brexpiprazole in MDD

Aripiprazole to Treat Bipolar Disorder

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia: Findings From a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder

Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study

Acute Treatment of Pediatric Bipolar I Disorder, Manic or Mixed Episode, With Aripiprazole: A Randomized, Double-Blind, Placebo-Controlled Study

The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia: A Pooled Post Hoc Analysis From 5 Short-Term Studies

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

Predicted Risk of Diabetes and Coronary Heart Disease in Patients With Schizophrenia: Aripiprazole Versus Standard of Care

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles